Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta Inc (NQ: NKTX )

3.370 +0.120 (+3.69%)
Streaming Delayed Price Updated: 10:59 AM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
What's Going With Cancer-Focused Nkarta Stock Today?
Nkarta Inc (NASDAQ: NKTX) received FDA clearance for its Investigational New Drug (IND) application to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate,  
Via Benzinga
Exposures Product Safety
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Nkarta
Via Benzinga
Analyst Expectations for Nkarta's Future
Via Benzinga
3 Promising Biotech Stocks That Will Make Early Investors Rich
Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 112 companies set new 52-week lows. 
Via Benzinga
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
3 Hidden Penny Stocks That Could Turn $100 into $10,000
These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors
Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)  
Via Benzinga
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET 
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential. 
Via InvestorPlace
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
3 Biotech Stocks to Watch for Potential Breakthroughs
These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future. 
Via InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros.... 
Via Benzinga
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.